Neurocrine Biosciences (NBIX) EBT (2010 - 2026)
Neurocrine Biosciences (NBIX) posted EBT of $246.8 million for Q1 2026, up 3.09% on a QoQ basis from $239.4 million in Q4 2025, and up 1578.91% year-over-year from $14.7 million in Q1 2025.
Neurocrine Biosciences (NBIX) EBT (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' EBT history runs 17 years deep, the most recent figure standing at $246.8 million for Q1 2026.
- Quarterly EBT rose 1578.91% year-over-year to $246.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $937.5 million (up 101.09% YoY) and the FY2025 annual result came in at $705.4 million, up 45.14% from the prior year.
- EBT was $246.8 million for Q1 2026 at Neurocrine Biosciences, up from $239.4 million in the prior quarter.
- Across five years, EBT topped out at $291.8 million in Q3 2025 and bottomed at -$103.3 million in Q1 2023.
- A 5-year average of $116.7 million and a median of $117.9 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2023 — EBT plunged 582.71% — and 2026, when it soared 1578.91%.
- Neurocrine Biosciences' EBT stood at $117.9 million in 2022, then jumped by 68.11% to $198.2 million in 2023, then decreased by 17.96% to $162.6 million in 2024, then soared by 47.23% to $239.4 million in 2025, then increased by 3.09% to $246.8 million in 2026.
- Business Quant data shows NBIX's EBT at $246.8 million in Q1 2026, $239.4 million in Q4 2025, and $291.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 437.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 758.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.90 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 318.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -247.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 246.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 87.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 246.80 Mn |
| Dec 31, 2025 | 239.40 Mn |
| Sep 30, 2025 | 291.80 Mn |
| Jun 30, 2025 | 159.50 Mn |
| Mar 31, 2025 | 14.70 Mn |
| Dec 31, 2024 | 162.60 Mn |
| Sep 30, 2024 | 190.30 Mn |
| Jun 30, 2024 | 98.60 Mn |
| Mar 31, 2024 | 34.50 Mn |
| Dec 31, 2023 | 198.20 Mn |
| Sep 30, 2023 | 115.60 Mn |
| Jun 30, 2023 | 121.60 Mn |
| Mar 31, 2023 | -103.30 Mn |
| Dec 31, 2022 | 117.90 Mn |
| Sep 30, 2022 | 97.90 Mn |
| Jun 30, 2022 | -23.30 Mn |
| Mar 31, 2022 | 21.40 Mn |
| Dec 31, 2021 | -13.80 Mn |
| Sep 30, 2021 | 30.50 Mn |
| Jun 30, 2021 | 57.50 Mn |